Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30985101 | 0.88 | MAPT (0.54) | GSK3BMAPTHPGDSCTNNB1WNT3A | |
| SCHEMBL1561350 | 0.88 | MAPT (0.54) | GSK3BMAPTHPGDSCTNNB1WNT3A | |
| SCHEMBL11476787 | 0.87 | GSK3B (0.54) | GSK3BMAPTHPGDSCTNNB1WNT3A | |
| SCHEMBL11636158 | 0.87 | HSD17B2 (0.51) | GSK3BMAPTHPGDSCTNNB1WNT3A | |
| SCHEMBL11401113 | 0.87 | ALDH1A1 (0.54) | GSK3BMAPTTSHRKMT2ASMN1; SMN2 | |
| SCHEMBL11466513 | 0.85 | GSK3B (0.49) | GSK3BMAPTHPGDSCTNNB1WNT3A | |
| SCHEMBL11466941 | 0.84 | GSK3B (0.51) | GSK3BMAPTHPGDSCTNNB1WNT3A | |
| SCHEMBL29678875 | 0.83 | MAPT (0.64) | MAPTTSHRKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5169870 | 0.83 | MAPT (0.64) | MAPTTSHRKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL2056261 | 0.83 | PTPN11 (0.47) | GSK3BMAPTKDM4ESMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1289980-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001090100-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-29 | — | — | WO | disclosed |
| US-4255575-A | HYPOTENSIVE, ANTISPASMODIC, ADRENERGIC BLOCKING AGENTS | RICHARDSON-MERRELL INC. (US) | 1981-03-10 | — | — | US | disclosed |
| US-4221808-A | Novel antihypertensive agent | RICHARDSON-MERRELL INC. (US) | 1980-09-09 | — | — | US | disclosed |
| US-4200755-A | ADRENERGIC BLOCKING AGENTS, ANTISPASMODIC AGENTS, HYPOTENSIVE AGENTS | RICHARDSON-MERRELL INC. (US) | 1980-04-29 | — | — | US | disclosed |
| US-4101579-A | Phenethanolamine ethers | ALLEN & HANBURYS LIMITED (GB) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | GSK3B 4101/4885MAPT 4864/4885HPGDS 173/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | GSK3B 4108/4885MAPT 4873/4885HPGDS 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.